 Adult Attention-Deficit/Hyperactivity Disorder and the Role of Depression PsychCast™ (72 Minutes)
Faculty: Timothy E. Wilens, MD, Andrew A. Nierenberg, MD, Anthony L. Rostain, MD, and Thomas J. Spencer, MD
This CME Expert Review PsychCast™ is jointly sponsored by the Mount Sinai School of Medicine and MBL Communications.
Release Date: June 2008
Termination Date: June 30, 2010
Estimated time to complete this activity: 1 hour
Medium: The content is delivered by PsychCast™ with a PDF or web-based Posttest
Acknowledgment of Commercial Support: Funding for this activity has been provided by an educational grant from Shire Pharmaceuticals Inc.
CME Course Director: This activity has been peer-reviewed and approved by Eric Hollander, MD, Chair and Professor of Psychiatry at Mount Sinai School of Medicine. Review Date: April 23, 2008
Section Editor: David L. Ginsberg, MD
Faculty Affiliation
Dr. Wilens is associate professor of psychiatry in the Department of Psychiatry at Harvard Medical School and director of substance abuse services in the Clinical and Research Program in Pediatric Psychopharmacology at Massachusetts General Hospital in Boston.
Dr. Nierenberg is associate director of the Depression Clinical and Research Program at Massachusetts General Hospital and professor of psychiatry at Harvard Medical School in Boston.
Dr. Rostain is professor of psychiatry and pediatrics and director of the Adult ADHD Treatment and Research Program at the University of Pennsylvania School of Medicine in Philadelphia.
Dr. Spencer is associate professor of psychiatry at Harvard Medical School and associate director of the Clinical and Research Program in Pediatric Psychopharmacology at Massachusetts General Hospital in Boston.
Faculty Disclosure Policy Statement
It is the policy of the Mount Sinai School of Medicine to ensure objectivity, balance, independence, transparency, and scientific rigor in all CME-sponsored educational activities. All faculty participating in the planning or implementation of a sponsored activity are expected to disclose to the audience any relevant financial relationships and to assist in resolving any conflict of interest that may arise from the relationship. Presenters must also make a meaningful disclosure to the audience of their discussions of unlabeled or unapproved drugs or devices. This information will be available as part of the course material.
Faculty Disclosure
Dr. Wilens is a consultant for Abbott, Cephalon, Eli Lilly, Ortho-McNeil, Merck, the National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), Novartis, and Shire; is on the speaker’s bureaus of Ortho-McNeil, Novartis, and Shire; and receives grant support from Abbott, Eli Lilly, Ortho-McNeil, Merck, NIH, NIDA, and Shire.
Dr. Wilens’ presentation includes discussion of unapproved/investigational uses of treatments for adult attention-deficit/hyperactivity disorder.
Dr. Nierenberg is a consultant to or serves on the advisory boards of AstraZeneca, Brain Cells, Bristol-Myers Squibb, Eli Lilly, Jazz, Merck, the National Institute of Mental Health (NIMH), Novartis, and Schering-Plough; and receives research support from the NIMH and Pfizer.
Dr. Rostain has received honoraria from Eli Lilly and Ortho-McNeil; and serves on the advisory board of Shire.
Dr. Spencer is on the advisory boards of Cephalon, Eli Lilly, GlaxoSmithKline, McNeil, Novartis, Pfizer, and Shire; is on the speaker’s bureaus of Eli Lilly, GlaxoSmithKline, Ortho-McNeil, Novartis, and Shire; and receives research support from Cephalon, Eli Lilly, GlaxoSmithKline, Ortho-McNeil, Novartis, and Shire.
Dr. Spencer’s presentation includes discussion of unapproved/investigational uses of atomoxetine, fluoxetine, paroxetine, and venlafaxine.
Dr. Ginsberg receives honoraria from AstraZeneca and GlaxoSmithKline.
Dr. Hollander reports no affiliation with or financial interest in any organization that may pose a conflict of interest.
Learning Objectives
- Evaluate recent research on the genetic and biologic evidence for associations between attention-deficit/hyperactivity disorder (ADHD) and depression
- Assess the treatments that would benefit patients with ADHD and comorbid depression and the risks of treating this patient subgroup.
Target Audience: This activity is designed to meet the educational needs of psychiatrists.
Accreditation Statement: This activity has been planned and implemented in accordance with the Essentials and Standards of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Mount Sinai School of Medicine and MBL Communications, Inc. The Mount Sinai School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation: The Mount Sinai School of Medicine designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Disclaimer: These are the opinions of the authors not of the sponsors or supporters. For more information, contact MBL Communications at cme@mblcommunications.com.
Minimum Hardware/Software Requirements
Macintosh: PowerPC processor, Mac OS 8.6, 9.0.4, 9.1, or Mac OS X, 64MB of RAM, 24MB of available hard-disk space, and Safari 1.x or 2.x.
Windows PC: Intel Pentium processor, Microsoft Windows 95 OSR 2.0, Windows 98 and 98 SE, Windows Millennium Edition, Windows NT 4.0 with Service Pack 5, Windows 2000, or Windows XP, 64MB of RAM, 24MB of available hard-disk space, and Internet Explorer 6.x and newer or Firefox 1.x and newer.
This CME Activity and Posttest information file is a PDF (Portable Document Format) document. To view this file, you will need Adobe Acrobat Reader, which is available free at www.adobe.com. Follow the instructions on that page to download and install the software.
Adult Attention-Deficit/Hyperactivity Disorder and the Role of Depression PsychCast™ (72 Minutes)
Faculty: Timothy E. Wilens, MD, Andrew A. Nierenberg, MD, Anthony L. Rostain, MD, and Thomas J. Spencer, MD
Abstract
Adult attention-deficit/hyperactivity disorder (ADHD) and depressive disorders have high overlapping prevalence rates. It is becoming increasingly clear that depression in individuals with ADHD is not an artifact of ADHD, nor is ADHD in individuals with depression an artifact of depression. The comorbidity of these disorders raises significant issues for diagnosis and treatment. Patients with both disorders often underreport their symptoms or have difficulty presenting a comprehensive picture of their conditions. To make an accurate diagnosis, clinicians must conduct a cognitive assessment accounting for both the patient’s presenting complaints and history. In addition, patients’ negative core beliefs and views must be assessed at diagnosis and addressed in the comprehensive treatment approach. In the treatment algorithm for both disorders, physicians should prioritize the worse condition. However, because depression is often viewed as the worse condition, physicians may be reluctant to treat comorbid ADHD. Physicians must recognize that comorbid ADHD carries a host of additional academic, occupational, and cognitive symptoms that demand treatment simultaneous to or following treatment for depression. Combined pharmacotherapy for ADHD and comorbid depression is often necessary and should be seriously considered. Approved pharmacologic treatments include stimulants and nonstimulants, while experimental treatments include antidepressants and arousal agents. In this Expert Roundtable PsychCast, Dr. Nierenberg discusses the epidemiology of depression and the neurologic theories behind depression and its treatment; Dr. Rostain explains the prevalence and clinical presentation of adult ADHD and comorbid depression; Dr. Wilens provides an overview of pharmacotherapy for comorbid adult ADHD and depression; and Dr. Spencer discusses treatment options for patients with these comorbid conditions.
In this Expert Roundtable PsychCast, Dr. Nierenberg discusses the epidemiology of depression and the neurologic theories behind depression and its treatment; Dr. Rostain explains the prevalence and clinical presentation of adult ADHD and comorbid depression; Dr. Wilens provides an overview of pharmacotherapy for comorbid adult ADHD and depression; and Dr. Spencer discusses treatment options for patients with these comorbid conditions.
To receive credit for this activity: Listen to the PsychCast™, reflect on the material presented, and complete the online CME Posttest/Evaluation here or to submit the CME Posttest/Evaluation by mail or fax, download a PDF here. To obtain credit, you should score 70% or better. The estimated time to complete the PsychCast™ and the posttest and evaluation is 1 hour. Successful completion of the posttest and evaluation will allow you to claim credit and print a certificate.
Early submission of this posttest is encouraged: please submit by June 1, 2010 to be eligible for credit. If you have any questions, please e-mail cme@mblcommunications.com.
Read the extended CME supplement related to this PsychCast™ activity here
Supported by Shire Pharmaceuticals Inc. |
Subscribe |
Download |
|
|
|
|
